Overview
- The study, published in Science on Aug. 27, 2026, found that chemically modified suppressor transfer RNAs (sup-tRNAs) delivered by a lung-targeted lipid nanoparticle restored full-length CFTR protein and functional chloride transport in human airway cells, mice, and patient-derived cystic fibrosis organoids.
- Adding the chemical N1-methyleadenosine to the engineered sup-tRNAs increased readthrough of premature stop codons, improved tRNA charging by aminoacyl-tRNA synthetases, lengthened functional persistence, and lowered innate immune activation.
- The team screened ionizable lipids to create a sup-tRNA-specific pulmonary LNP formulation and showed those particles survive nebulization, which supports the feasibility of an inhaled, at-home delivery route for lung-targeted treatment.
- In a patient-derived organoid with a complex CFTR genotype that did not respond to CFTR modulators alone, cotreatment with the modified sup-tRNAs and the modulator Trikafta produced functional rescue, showing the approach can complement existing drugs.
- The results are preclinical and funded by multiple agencies; investigators and outside experts stress the need for systematic safety testing, dosing and carrier optimization, and regulatory work before human trials despite the platform’s potential to address many diseases caused by nonsense mutations.